AU2017206108B2 - Combination of a chromene compound and a second active agent - Google Patents

Combination of a chromene compound and a second active agent Download PDF

Info

Publication number
AU2017206108B2
AU2017206108B2 AU2017206108A AU2017206108A AU2017206108B2 AU 2017206108 B2 AU2017206108 B2 AU 2017206108B2 AU 2017206108 A AU2017206108 A AU 2017206108A AU 2017206108 A AU2017206108 A AU 2017206108A AU 2017206108 B2 AU2017206108 B2 AU 2017206108B2
Authority
AU
Australia
Prior art keywords
compound
chromene
group
cancer
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017206108A
Other languages
English (en)
Other versions
AU2017206108A1 (en
Inventor
Eduardo J. Martinez
Bobby W. SANDAGE
John J. Talley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euclises Pharmaceuticals Inc
Original Assignee
Euclises Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euclises Pharmaceuticals Inc filed Critical Euclises Pharmaceuticals Inc
Publication of AU2017206108A1 publication Critical patent/AU2017206108A1/en
Application granted granted Critical
Publication of AU2017206108B2 publication Critical patent/AU2017206108B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
AU2017206108A 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent Active AU2017206108B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276713P 2016-01-08 2016-01-08
US62/276,713 2016-01-08
US201662277225P 2016-01-11 2016-01-11
US62/277,225 2016-01-11
PCT/US2017/012737 WO2017120591A1 (en) 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent

Publications (2)

Publication Number Publication Date
AU2017206108A1 AU2017206108A1 (en) 2018-08-02
AU2017206108B2 true AU2017206108B2 (en) 2021-10-28

Family

ID=59274050

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017206108A Active AU2017206108B2 (en) 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent

Country Status (8)

Country Link
US (2) US20170196835A1 (https=)
EP (1) EP3400218A4 (https=)
JP (1) JP6942726B2 (https=)
KR (1) KR20180100652A (https=)
CN (1) CN108779091B (https=)
AU (1) AU2017206108B2 (https=)
MX (1) MX388579B (https=)
WO (1) WO2017120591A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
CA3069400A1 (en) * 2017-07-20 2019-01-24 National University Corporation Hokkaido University Combination use of inhibitor targeting pd-1/pd-l1 and cox-2 inhibitor
TR201900059A2 (tr) 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
TWI869398B (zh) * 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
CN114650815A (zh) * 2019-10-28 2022-06-21 Enzychem生命科学株式会社 癌症治疗的方法及组成物
KR20220100904A (ko) 2019-11-12 2022-07-18 남미 테라퓨틱스, 인크. 암의 치료에 유용한 ido 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
AU2021263914A1 (en) 2020-04-29 2022-11-03 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
US20250084048A1 (en) * 2021-10-07 2025-03-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
KR102889598B1 (ko) * 2023-02-16 2025-11-21 주식회사 재인알앤피 신규한 데커신 유도체, 및 이의 비소세포폐암 예방 또는 치료 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140099254A1 (en) * 2012-08-14 2014-04-10 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150133538A1 (en) * 2012-06-18 2015-05-14 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Deuterated Benzopyran Compounds and Application Thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040127470A1 (en) 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US20020103141A1 (en) 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
CA2692973A1 (en) 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Patient selection and therapeutic methods using markers of prostaglandin metabolism
CN103012350B (zh) 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
CN103044477B (zh) 2012-12-07 2015-08-05 中国科学院广州生物医药与健康研究院 三甲基硅取代苯并吡喃类化合物及其应用
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
EP2981281B1 (en) * 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP3084005A4 (en) 2013-12-17 2017-08-02 Merck Sharp & Dohme Corp. Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133538A1 (en) * 2012-06-18 2015-05-14 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Deuterated Benzopyran Compounds and Application Thereof
US20140099254A1 (en) * 2012-08-14 2014-04-10 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease

Also Published As

Publication number Publication date
EP3400218A4 (en) 2019-09-18
US20220265602A1 (en) 2022-08-25
US12544356B2 (en) 2026-02-10
MX388579B (es) 2025-03-20
WO2017120591A1 (en) 2017-07-13
MX2018008433A (es) 2019-03-28
KR20180100652A (ko) 2018-09-11
JP2019501224A (ja) 2019-01-17
AU2017206108A1 (en) 2018-08-02
CA3010848A1 (en) 2017-07-13
CN108779091A (zh) 2018-11-09
CN108779091B (zh) 2022-12-27
US20170196835A1 (en) 2017-07-13
EP3400218A1 (en) 2018-11-14
JP6942726B2 (ja) 2021-09-29

Similar Documents

Publication Publication Date Title
US12544356B2 (en) Combination of a chromene compound and a second active agent
US10945994B2 (en) Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body
Ortiz-Cuaran et al. Precision medicine approaches to overcome resistance to therapy in head and neck cancers
KR20220030222A (ko) Tead 억제제 및 이의 용도
KR102705821B1 (ko) 항암제
US10335494B2 (en) Combination of aurora kinase inhibitors and anti-CD30 antibodies
JP2023553866A (ja) Ｔｅａｄ阻害剤、及びその使用
JP2024514836A (ja) Ｃｂｌ－ｂ阻害化合物との組み合わせ療法
AU2016271475A1 (en) Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
WO2019144126A1 (en) Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
KR20210034613A (ko) 퀴놀린 유도체 및 항체의 약물 조합
JP2021531311A (ja) ナフチリジン化合物およびその使用
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
KR20250040894A (ko) Mek 억제제 및 이의 용도
CA3010848C (en) Combination of a chromene compound and a second active agent
HK40000167A (en) Combination of a chromene compound and a second active agent
HK40000167B (en) Combination of a chromene compound and a second active agent
US20240309090A1 (en) Modulation of androgen signaling to innate immune killing of prostate cancer
KR20260022961A (ko) 암 치료를 위한 ioa-244, pd-1 또는 pd-l1 억제제 및 화학요법제의 병용

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)